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In an ideal world, universal access to healthcare should be 
achievable; all COVID-19 patients should have access to therapies 
that improve outcomes. These include existing, repurposed and 
novel therapies. Novel therapies need to be safe and effective, and 
a well-established path for obtaining information regarding safety 
and efficacy has been in place for many years. The pandemic has 
seen an acceleration in these processes: existing medicines are 
being rapidly repurposed, there is a massive drive to develop novel 
treatments and vaccines, and access to experimental treatments is 
being granted on compassionate grounds. 
The management of COVID-19 has evolved rapidly, for a disease 
that we have known for less than a year. Invasive ventilation for 
critically ill patients dominated the headlines in the early days of the 
pandemic, and massive drives were initiated to manufacture more 
ventilators. Several antimicrobial medications, notably for Ebola 
(remdesivir), HIV (lopinavir/ritonavir), malaria (chloroquine/
hydroxychloroquine) and bacterial respiratory infections 
(azithromycin) have been repurposed in an attempt to reduce 
viral load in the early stages of the disease. With an increased 
understanding of the pathogenesis of COVID-19 has come the 
recognition that many of the consequences of SARS-CoV-2 
infection are the result of the body’s response to the virus rather 
than the virus itself. Multi-organ involvement is the consequence 
of systemic hyperinflammation and a state of hypercoagulation and 
occurs as viral load decreases. Ironically, in the midst of efforts to 
identify novel approaches to management, we appear to be relying 
on those that are tried and tested: oxygen administration via 
non-invasive means, dexamethasone and other corticosteroids for 
inflammation, and anticoagulants to prevent thrombosis.
The reasons for the emergence of extremes in behaviour during 
the pandemic are multiple and complex, not the least of which are 
political and economic. Coinciding with the pandemic has been 
the build-up to the US presidential election, in which COVID-
19 has featured prominently. With the USA having the highest 
number of deaths globally and one of the highest percentages of 
total population affected, strong opinions have been voiced and 
criticisms have abounded. It is not the purpose of this editorial to 
provide an opinion or to add to the chorus of experts; suffice it to 
note that social media and television have provided access to highly 
granular and deeply personal information on everyone concerned, 
and this has impacted on public opinion and readiness to adhere 
to guidance.
Conflicting views, changes in opinion, the emergence of 
alternative theories and proponents of the ‘deep state’ have added 
further to the confusion and have undermined the trust of the 
general public. Much of this behaviour has had an impact on access 
to therapies for COVID-19, or is threatening to do so. Hoarding 
of medicines such as remdesivir and ongoing discussions about 
access to vaccines are two cases in point. This situation has been 
aggravated by the so-called ‘infodemic’, a phrase coined in 2003 
and recently used by the World Health Organization (WHO)[1] to 
describe the unprecedented deluge of information to which the 
global population has been subjected. Suspicion abounds regarding 
efforts to promote the use of non-pharmacological interventions, as 
well as existing and novel therapies, and the anti-vaxxer movement 
has gained momentum.
The world reacted strongly to the news that President Donald Trump 
had COVID-19, and a number of critical issues were brought to the 
fore. The one that stands out in the context of this editorial relates to 
access to novel and potentially curative medicines. Human life cannot 
be quantified in monetary terms, and it is likewise not possible to place 
a higher value on one life over another. Universal health coverage as 
defined by the WHO means that ‘all people and communities can 
use the promotive, preventive, curative, rehabilitative and palliative 
health services they need, of sufficient quality to be effective, while 
also ensuring that the use of these services does not expose the user 
to financial hardship’.[2] In practice however, it appears that access to 
and quality of healthcare are directly proportional to socioeconomic 
status, and quality of healthcare is adversely affected in a resource-
poor setting.
The universal right to healthcare is based on the philosophical 
notion of distributive justice, which advocates for a just allocation/
distribution of goods among members of society. COVID-19 
has highlighted the ever-widening gap between the wealthy and 
the poor. One way of reducing this gap could be to include a 
representative cross-section of the entire population in clinical 
trials for experimental treatments, and not to favour one group or 
individual over another.
How much evidence is required before an experimental treatment 
can be administered with an acceptable degree of safety? A case 
in point is convalescent plasma, which appears to be safe but for 
which there is so far insufficient efficacy data to support its use 
on a large scale. One of the active components is believed to be 
neutralising antibodies to SARS-CoV-2. Could the administration of 
these antibodies on their own suffice? President Trump’s physicians 
believed this to be the case, and recently treated him with a 
cocktail of neutralising antibodies, REGN-COV2, manufactured 
by Regeneron.[3] Although this drug has been shown to reduce viral 
load in non-hospitalised patients, and entered phase III clinical 
trials in July, questions regarding sustainability and long-term effects 
cannot be answered in such a short space of time. Equally important 
is the fact that the US President’s treatment also included remdesivir, 
dexamethasone, supplemental oxygen, zinc, vitamin D, famatodine, 
melatonin and aspirin;[4] the consequences of administering this 
combination are not known. It is still early days in President Trump’s 
illness (at the time of writing, 7 October 2020), and the emergence of 
a very real category of so-called ‘long-haulers’, people who experience 
symptoms over a long period as a consequence of SARS-CoV-2 
infection, may become important over time.
One might ask: what motivated the choice of this treatment 
approach? This is not the forum to attempt to answer this question; 
suffice it to say that an element of calculated risk is likely to have 
been involved. Were the President and his physicians playing 
Russian roulette? The stakes could not be higher, given that election 
day is less than a month away.
2020 is likely to remain one of the most tumultuous and 
disruptive years in history. It has taught us that we need to rely on 
science and avoid being misled by dubious ‘facts’ that are disguised 
as scientific evidence. In times like these, it is useful to recall the 
words of Rudyard Kipling’s inspirational poem ‘If ’ (1895) (I am sure 
that the last line of the poem would have reflected greater sensitivity 
to gender equality had he written this in 2020):
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If you can keep your head when all about you 
Are losing theirs and blaming it on you, 
If you can trust yourself when all men doubt you, 
But make allowance for their doubting too; 
If you can wait and not be tired by waiting, 
Or being lied about, don’t deal in lies, 
Or being hated, don’t give way to hating, 
And yet don’t look too good, nor talk too wise:
If you can dream – and not make dreams your master, 
If you can think – and not make thoughts your aim; 
If you can meet with Triumph and Disaster 
And treat those two impostors just the same; 
If you can bear to hear the truth you’ve spoken 
Twisted by knaves to make a trap for fools, 
Or watch the things you gave your life to, broken, 
And stoop and build ’em up with worn-out tools:
If you can make one heap of all your winnings 
And risk it all on one turn of pitch-and-toss, 
And lose, and start again at your beginnings 
And never breathe a word about your loss; 
If you can force your heart and nerve and sinew 
To serve your turn long after they are gone, 
And so hold on when there is nothing in you 
Except the Will which says to them: ‘Hold on!’
If you can talk with crowds and keep your virtue, 
Or walk with kings – nor lose the common touch, 
If neither foes nor loving friends can hurt you, 
If all men count with you, but none too much; 
If you can fill the unforgiving minute 
With sixty seconds’ worth of distance run, 
Yours is the Earth and everything that’s in it, 
And – which is more – you’ll be a Man, my son!
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